IL307992B2 - Isoxazoline parasiticide formulations and methodsfor treating blepharitis - Google Patents

Isoxazoline parasiticide formulations and methodsfor treating blepharitis

Info

Publication number
IL307992B2
IL307992B2 IL307992A IL30799223A IL307992B2 IL 307992 B2 IL307992 B2 IL 307992B2 IL 307992 A IL307992 A IL 307992A IL 30799223 A IL30799223 A IL 30799223A IL 307992 B2 IL307992 B2 IL 307992B2
Authority
IL
Israel
Prior art keywords
composition
use according
patient
isoxazoline parasiticide
delivered
Prior art date
Application number
IL307992A
Other languages
Hebrew (he)
Other versions
IL307992A (en
IL307992B1 (en
Inventor
Shawn D Hickok
Bobak Robert Azamian
Joseph G Vehige
Douglas Michael Ackermann
Original Assignee
Tarsus Pharmaceuticals Inc
Shawn D Hickok
Bobak Robert Azamian
Joseph G Vehige
Douglas Michael Ackermann
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=66814591&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL307992(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tarsus Pharmaceuticals Inc, Shawn D Hickok, Bobak Robert Azamian, Joseph G Vehige, Douglas Michael Ackermann filed Critical Tarsus Pharmaceuticals Inc
Publication of IL307992A publication Critical patent/IL307992A/en
Publication of IL307992B1 publication Critical patent/IL307992B1/en
Publication of IL307992B2 publication Critical patent/IL307992B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Claims (53)

1. 307992/ -42- Claims 1. An ophthalmic composition for use in reducing eyelid collarettes in a human patient, wherein the composition comprises an effective amount of an isoxazoline parasiticide and a pharmaceutically acceptable vehicle, and wherein the composition is topically delivered to one or more of the eyes, eyelids, or eyelashes of the patient.
2. The composition for use according to Claim 1, wherein the ophthalmic composition comprises an eye drop.
3. The composition for use according to Claim 1 or 2, wherein the composition does not include any essential oils.
4. The composition for use according to any one of the preceding claims, wherein the isoxazoline parasiticide is selected from the group consisting of: fluralaner, sarolaner, lotilaner, afoxolaner and fluxametamide.
5. The composition for use according to Claim 4, wherein the isoxazoline parasiticide comprises lotilaner.
6. The composition for use according to any one of the preceding claims, wherein the isoxazoline parasiticide is the sole active ingredient of the composition.
7. The composition for use according to any one of the preceding claims, wherein the composition comprises a castor oil, but not a polysorbate.
8. An ophthalmic composition for use in reducing eyelid collarettes in a human patient, wherein the composition comprises an effective amount of an isoxazoline parasiticide, a pharmaceutically acceptable vehicle, and a castor oil, wherein the isoxazoline parasiticide is the sole active ingredient of the composition, and wherein the composition is topically delivered to one or more of the eyes, eyelids, or eyelashes of the patient. -43-
9. The composition for use according to Claim 8, wherein the patient’s eyes are closed upon topically administering the composition, such that the composition contacts orifices of Meibomian glands of the patient and outside of eyelid margins of the patient.
10. The composition for use according to Claim 9, wherein the composition is intended to be spread onto the eyelashes and follicles of the eyelashes.
11. The composition for use according to Claim 10, wherein the composition is intended to be spread onto the eyelashes and follicles of the eyelashes with an applicator.
12. The composition for use according to any one of Claims 8 to 11, wherein the composition comprises from 0.001% to 1% of the isoxazoline parasiticide.
13. The composition for use according to any one of Claims 8 to 12, wherein the composition is intended to be administered at least once daily for at least 2 weeks.
14. The composition for use according to Claim 13, wherein the composition is intended to be administered at least once daily for at least 4 weeks.
15. The composition for use according to any one of Claims 8 to 14, wherein the isoxazoline parasiticide comprises lotilaner.
16. An ophthalmic composition for use in reducing eyelid collarettes in a human patient, wherein the composition comprises an effective amount of an isoxazoline parasiticide and a pharmaceutically acceptable vehicle, wherein the isoxazoline parasiticide is the sole active ingredient of the composition, wherein the composition is topically delivered to one or more of the eyes, eyelids, or eyelashes of the patient, and wherein the volume of the composition delivered is less than 100 microliters.
17. The composition for use according to Claim 16, wherein the composition is intended to be administered following a first assessment of a quantity of Demodex mites on an anatomical structure of the patient indicating the quantity of Demodex mites is greater than a predetermined value.
18. The composition for use according to Claim 17, wherein the predetermined value is 1 mite per lash. -44-
19. The composition for use according to Claim 16, wherein the composition is intended to be administered following a first assessment of a quantity of collarettes on an anatomical structure of the patient indicating the quantity of collarettes is greater than a predetermined value.
20. The composition for use according to Claim 19, wherein the predetermined value is 3 collarettes.
21. The composition for use according to Claim 19, wherein the predetermined value is 10 collarettes.
22. The composition for use according to any one of Claims 16 to 21, wherein the isoxazoline parasiticide comprises lotilaner.
23. A topical composition for use in treating an ocular Demodex infestation in a human patient, wherein the composition comprises an effective amount of an isoxazoline parasiticide and a pharmaceutically acceptable vehicle, and wherein the composition is formulated as a gel, an ointment, or a cream.
24. The composition for use according to Claim 23, wherein the composition is topically delivered to one or more of the eyes, eyelids, or eyelashes of the patient.
25. The composition for use according to Claim 23 or 24, wherein from 0.01% to 1% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
26. The composition for use according to Claim 25, wherein from 0.15% to 0.40% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
27. The composition for use according to Claim 26, wherein 0.25% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
28. The composition for use according to any one any one of Claims 23 to 27, wherein the isoxazoline parasiticide is selected from the group consisting of: fluralaner, sarolaner, lotilaner, afoxolaner and fluxametamide.
29. The composition for use according to Claim 28, wherein the isoxazoline parasiticide comprises lotilaner. -45-
30. The composition for use according to any one of Claims 23 to 29, wherein the composition does not include any essential oils.
31. The composition for use according to any one of Claims 23 to 30, wherein the composition does not include tea tree oil.
32. The composition for use according to any one of Claims 23 to 31, wherein the isoxazoline parasiticide is the sole active ingredient of the composition.
33. The composition for use according to any one of Claims 23 to 32, wherein the composition is topically administered at least once daily for at least 2 weeks.
34. The composition for use according to Claim 33, wherein the composition is topically administered at least once daily for at least 4 weeks.
35. The composition for use according to Claim 34, wherein the composition is topically administered at least once daily for at least 6 weeks.
36. The composition for use according to any Claim 33, wherein the composition is topically administered at least twice daily for at least 2 weeks.
37. The composition for use according to any one of Claims 23 to 36, wherein the composition comprises a castor oil.
38. The composition for use according to Claim 37, wherein the castor oil comprises hydrogenated castor oil.
39. A dermatological composition for use in treating rosacea in a human patient, wherein the composition comprises an effective amount of an isoxazoline parasiticide and a pharmaceutically acceptable vehicle, and wherein the composition is formulated as a gel, an ointment, or a cream.
40. The composition for use according to Claim 39, wherein the composition is topically delivered to one or more of the eyes, eyelids, or eyelashes of the patient.
41. The composition for use according to Claim 39 or 40, wherein from 0.001% to 10% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
42. The composition for use according to Claim 41, wherein from 0.1% to 10% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient. -46-
43. The composition for use according to Claim 41, wherein from 0.01% to 5% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
44. The composition for use according to Claim 43, wherein 2% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
45. The composition for use according to Claim 43, wherein 1% of the isoxazoline parasiticide with respect to the total weight of the composition is delivered to the patient.
46. The composition for use according to any one any one of Claims 39 to 45, wherein the isoxazoline parasiticide is selected from the group consisting of: fluralaner, sarolaner, lotilaner, afoxolaner and fluxametamide.
47. The composition for use according to Claim 46, wherein the isoxazoline parasiticide comprises lotilaner.
48. The composition for use according to any one of Claims 39 to 47, wherein the composition does not include any essential oils.
49. The composition for use according to any one of Claims 39 to 48, wherein the isoxazoline parasiticide is the sole active ingredient of the composition.
50. The composition for use according to any one of Claims 39 to 49, wherein the composition is topically administered at least once daily for at least 2 weeks.
51. The composition for use according to Claim 50, wherein the composition is topically administered at least once daily for at least 4 weeks.
52. The composition for use according to Claim 51, wherein the composition is topically administered at least once daily for at least 6 weeks.
53. The composition for use according to Claim 50, wherein the composition is topically administered at least twice daily for at least 2 weeks.
IL307992A 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methodsfor treating blepharitis IL307992B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762599213P 2017-12-15 2017-12-15
US201862615855P 2018-01-10 2018-01-10
US201862626612P 2018-02-05 2018-02-05
US201862689787P 2018-06-25 2018-06-25
US201862746498P 2018-10-16 2018-10-16
PCT/US2018/065849 WO2019118928A1 (en) 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methods for treating blepharitis

Publications (3)

Publication Number Publication Date
IL307992A IL307992A (en) 2023-12-01
IL307992B1 IL307992B1 (en) 2024-11-01
IL307992B2 true IL307992B2 (en) 2025-03-01

Family

ID=66814591

Family Applications (3)

Application Number Title Priority Date Filing Date
IL275339A IL275339B2 (en) 2017-12-15 2018-12-14 Parasitic formulations containing isoxazoline and methods for treating blepharitis
IL316352A IL316352A (en) 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methodsfor treating blepharitis
IL307992A IL307992B2 (en) 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methodsfor treating blepharitis

Family Applications Before (2)

Application Number Title Priority Date Filing Date
IL275339A IL275339B2 (en) 2017-12-15 2018-12-14 Parasitic formulations containing isoxazoline and methods for treating blepharitis
IL316352A IL316352A (en) 2017-12-15 2018-12-14 Isoxazoline parasiticide formulations and methodsfor treating blepharitis

Country Status (19)

Country Link
US (14) US10835517B2 (en)
EP (2) EP4397375A3 (en)
JP (2) JP2021506971A (en)
KR (4) KR20200111177A (en)
CN (3) CN119157876A (en)
AU (3) AU2018385766B2 (en)
BR (1) BR112020012018A2 (en)
CA (1) CA3085787A1 (en)
DK (1) DK3723739T3 (en)
ES (1) ES2981130T3 (en)
FI (1) FI3723739T3 (en)
HU (1) HUE067461T2 (en)
IL (3) IL275339B2 (en)
MX (2) MX2020006309A (en)
PL (1) PL3723739T3 (en)
PT (1) PT3723739T (en)
SI (1) SI3723739T1 (en)
WO (1) WO2019118928A1 (en)
ZA (1) ZA202004155B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
CN119157876A (en) * 2017-12-15 2024-12-20 塔苏斯制药有限公司 Isoxazoline anthelmintic formulations and methods for treating blepharitis
CA3107590A1 (en) 2018-07-27 2020-01-30 Aperta Biosciences, Llc Spinosyn formulations for treatment of demodex-induced ocular and facial conditions
US12502377B2 (en) 2019-04-04 2025-12-23 Tarsus Pharmaceuticals, Inc. Method of eradicating ticks that attach to humans using lotilaner formulations
AU2020295570A1 (en) * 2019-06-19 2022-02-10 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
US20250275924A1 (en) * 2022-04-22 2025-09-04 Attillaps Holdings Inc. Anticholinergic Agents and Muscarinic Agonists for the Treatment of Demodex Related Conditions
WO2024168149A1 (en) * 2023-02-10 2024-08-15 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
CN120916785A (en) * 2023-04-08 2025-11-07 林颂然 Methods for treating corneal damage
CN119789854A (en) * 2023-08-04 2025-04-08 Ads医疗有限责任公司 Compositions and methods for delivering ophthalmic actives

Family Cites Families (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2361974A (en) 1940-02-07 1944-11-07 John A Rietmann Electrolytic cell
US3781355A (en) 1969-12-12 1973-12-25 Boots Pure Drug Co Ltd Pesticidal compounds and compositions
US3864497A (en) 1970-12-01 1975-02-04 Boots Pure Drug Co Ltd Acaricidal and insecticidal 1,5-diphenyl-3-methyl-1,3,5-triazapenta-1,4-diener
JPS6033429Y2 (en) 1975-09-30 1985-10-04 株式会社田村電機製作所 Frequency switching mechanism
US4389397A (en) 1980-08-04 1983-06-21 Merck & Co., Inc. Solubilization of ivermectin in water
US5019392A (en) 1988-03-03 1991-05-28 Micro-Pak, Inc. Encapsulation of parasiticides
US4957918A (en) 1988-06-09 1990-09-18 Leonard Bloom Topical treatment of blepharitis
US5614545A (en) 1988-06-09 1997-03-25 Leonard Bloom Topical composition for treatment of blepharitis
US6001822A (en) 1989-04-11 1999-12-14 Pfizer Inc. Antiparasitic formulations
FR2656526B1 (en) 1990-01-02 1994-10-28 Virbac Sa Laboratoires CONTROLLED RELEASE DEVICE AND PREPARATION METHOD.
AU6021794A (en) 1993-01-11 1994-08-15 Allergan, Inc. Ophthalmic compositions comprising benzyllauryldimethylammonium chloride
US5632999A (en) 1993-08-18 1997-05-27 Virbac, Inc. Sustained release pyriproxifen compositions for parasite control
US5981500A (en) 1994-01-12 1999-11-09 Pfizer Inc. Antiparasitic agents related to the milbemycins and avermectins
FR2729539B1 (en) 1995-01-23 1997-04-11 Virbac Lab DEVICE FOR CONTROLLED RELEASE OF CHEMICAL SUBSTANCES, FOR FIXING ON AN ANIMAL AND METHOD FOR PREPARING SAID DEVICE
DE19613972A1 (en) 1996-04-09 1997-10-16 Bayer Ag Injection formulations of avermectins and milbemycins based on castor oil
RU2126668C1 (en) 1996-10-17 1999-02-27 Багров Сергей Николаевич Ointment demalon for treatment of patients with blepharitis
FR2761886B1 (en) 1997-04-14 2000-05-05 Virbac Sa COMPOSITIONS CONTAINING AT LEAST ONE CATIONIC POLYMER AND AT LEAST ONE ACTIVE MOLECULE CONTAINED IN AT LEAST ONE MICRO OR NANOPARTICLE VECTOR AND THEIR USE FOR THE TREATMENT OF LIVE OR INERT SURFACES
ATE248773T1 (en) 1997-10-14 2003-09-15 Isp Investments Inc STABILIZED CONCENTRATES OF WATER UNSTABLE AZA COMPOUNDS AND WATER/OIL MINI EMULSIONS THEREOF
US5968990A (en) 1997-10-14 1999-10-19 Isp Investments Inc. Water-dilutable, microemulsion concentrate and pour-on formulations thereof
PT1676579E (en) 1998-05-08 2009-03-24 Univ Miami Use of sub-antimicrobial tetracyclines for treating ocular rosacea
US5952372A (en) 1998-09-17 1999-09-14 Mcdaniel; William Robert Method for treating rosacea using oral or topical ivermectin
GB9825402D0 (en) 1998-11-19 1999-01-13 Pfizer Ltd Antiparasitic formulations
US7897559B2 (en) 2000-06-29 2011-03-01 Parks L Dean Dermatological composition and kit containing avermectin compound for treating dermatological conditions
US6696067B2 (en) 2001-04-12 2004-02-24 Ondeo Nalco Company Cosmetic compositions containing dispersion polymers
US6881726B2 (en) 2001-12-24 2005-04-19 Dow Pharmaceutical Sciences Aqueous compositions containing metronidazole
IL147921A0 (en) 2002-01-31 2002-08-14 Abdulrazik Mohammad A method for treating central nervous system disorders by ocular dosing
AU2003215011A1 (en) 2002-02-08 2003-09-02 Mcneil-Ppc, Inc. Topical ivermectin composition
US7906128B2 (en) 2002-10-21 2011-03-15 Wyeth Llc Use of neuronal sodium channel antagonists for the control of ectoparasites in homeothermic animals
JP5711867B2 (en) 2003-04-24 2015-05-07 ガルデルマ・ソシエテ・アノニム Use of ivermectin for the treatment of dermatological diseases
FR2854074B1 (en) 2003-04-24 2007-11-23 Galderma Res & Dev USE OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS
US7531186B2 (en) 2003-12-17 2009-05-12 Merial Limited Topical formulations comprising 1-N-arylpyrazole derivatives and amitraz
CN101768129B (en) 2004-03-05 2012-05-23 日产化学工业株式会社 Preparation intermediate of isoxazoline substituted benzamide compound
EP1758576A1 (en) 2004-03-12 2007-03-07 Christian Diehl Topical and intravaginal microbicidal and antiparasitic compositions comprising quassinoids or quassionid-containing plant extracts
US8541413B2 (en) 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
TWI350728B (en) 2004-10-08 2011-10-21 Wyeth Corp Amitraz compositions
US9186345B2 (en) 2004-10-12 2015-11-17 Hakon Hakonarson Method of treating skin diseases
GB2419093A (en) 2004-10-12 2006-04-19 Ernir Snorrason Acetylcholinesterase inhibitors for the treatment of skin
DE102004053964A1 (en) 2004-11-09 2006-05-11 Bayer Healthcare Ag Remedy for demodicosis
KR101319772B1 (en) 2004-11-09 2013-10-23 노바갈리 파르마 에스 에이 Ophthalmic emulsions containing an immunosuppressive agent
WO2006119174A1 (en) 2005-04-30 2006-11-09 Ocular Surface Center, P.A. Method for treating ocular demodex
FR2886851B1 (en) 2005-06-10 2007-10-05 Galderma Sa COMPOSITION BASED ON AVERMECTIN AND METRONIDAZOLE, IN PARTICULAR FOR THE TREATMENT OF ROSACEA
AU2006285613B2 (en) 2005-09-02 2011-11-17 Nissan Chemical Corporation Isoxazoline-substituted benzamide compound and harmful organism-controlling agent
FR2891460B1 (en) 2005-09-30 2010-07-30 Galderma Sa USE OF AT LEAST ONE COMPOUND OF THE AVERMECTIN FAMILY FOR THE TREATMENT OF OPHTHALMIC DISEASES DUE TO DEMODEX FOLLICULORUM.
BRPI0620668A2 (en) 2005-12-14 2011-11-22 Du Pont compound of formula 1, composition comprising compound, invertebrate pest control composition, spray composition, bait composition, trap device, invertebrate pest control methods, cockroach, ants or termites control method and protection method. seeds against invertebrate pests
TW200803740A (en) 2005-12-16 2008-01-16 Du Pont 5-aryl isoxazolines for controlling invertebrate pests
TWI412322B (en) 2005-12-30 2013-10-21 Du Pont Isoxazolines for controlling invertebrate pests
FR2900052B1 (en) 2006-04-19 2011-02-18 Galderma Sa COMPOSITION COMPRISING AT LEAST ONE AQUEOUS PHASE AND AT LEAST ONE FATTY PHASE COMPRISING IVERMECTIN
MX2008013307A (en) 2006-04-20 2008-10-27 Du Pont Pyrazolines for controlling invertebrate pests.
JP2008044880A (en) 2006-08-15 2008-02-28 Bayer Cropscience Ag Insecticidal isooxazolines
JP5256753B2 (en) 2007-03-29 2013-08-07 住友化学株式会社 Isoxazoline compounds and their pest control applications
RU2009141185A (en) 2007-04-10 2011-05-20 Байер КропСайенс АГ (DE) INSECTICIDAL DERIVATIVES OF ARILIZOXOXAZOLINE
WO2008138516A1 (en) 2007-05-09 2008-11-20 Ganial Immunoterapeutics Inc. (s,r)-3-phenyl-4,5 dihydro-5-isoxazole acetic acid-nitric oxide and use thereof as anti-cancer and antiviral agent
WO2008154528A2 (en) 2007-06-13 2008-12-18 E. I. Du Pont De Nemours And Company Isoxazoline insecticides
TWI556741B (en) 2007-08-17 2016-11-11 英特威特國際股份有限公司 Isoxazoline compositions and their use as antiparasitics
US8128968B2 (en) 2007-08-29 2012-03-06 Tissuetech, Inc. Compositions and methods for treating Demodex infestations
MX2010003557A (en) 2007-10-03 2010-04-12 Du Pont Naphthalene isoxazoline compounds for control of invertebrate pests.
FR2922108A1 (en) 2007-10-11 2009-04-17 Virbac Sa USE OF A 1-N- (HALO-3-PYRIDYLMETHYL) -N-METHYLAMINO-1-ALKYLAMINO -2-NITROETHYLENE DERIVATIVE FOR THE PREPARATION OF A VETERINARY PHARMACEUTICAL COMPOSITION FOR CONTROLLING CHIPS
FR2925337B1 (en) 2007-12-21 2010-01-15 Virbac PHARMACEUTICAL COMPOSITION CONTAINING AN N-PHENYLPYRAZOLE DERIVATIVE AND GLYCOFUROL, USE FOR THE PREPARATION OF A TOPICAL VETERINARY DRUG FOR CONTROLLING CHIPS
AU2009228205A1 (en) 2008-03-26 2009-10-01 Eric Donnenfeld Methods for improving lid margin and tear film function and treatment of lid margin disease using tetracycline family antibiotics
US20090317503A1 (en) 2008-06-20 2009-12-24 Ocusoft, Inc. Eyelid Preparation and Method of Use
WO2010003923A1 (en) 2008-07-09 2010-01-14 Basf Se Pestcidal active mixtures comprising isoxazoline compounds i
CA2973871C (en) 2008-07-09 2019-09-10 Nissan Chemical Industries, Ltd. Production method of isoxazoline-substituted benzoic acid amide compound
SG171751A1 (en) 2008-11-19 2011-07-28 Merial Ltd Compositions comprising an aryl pyrazole and/ or a formamidine methods and uses thereof
US9173728B2 (en) 2008-11-19 2015-11-03 Merial Inc. Multi-cavity container having offset indentures for dispensing fluids
EP2375905B1 (en) 2008-12-16 2012-12-05 Virbac Pharmaceutical composition containing an n-phenylpyrazole derivative, and use thereof for preparing a topical veterinary drug for flea control
PL2379537T3 (en) * 2008-12-19 2013-03-29 Elanco Tiergesundheit Ag Isoxazoline derivatives and their use as pesticide
US8313752B2 (en) 2009-04-14 2012-11-20 Merial Limited Macrocyclic lactone combination compositions, vaccines and methods for producing same
FR2945797B1 (en) 2009-05-20 2015-11-06 Virbac Sa FOOD, PHARMACEUTICAL OR VETERINARY SAFETY PACKAGING AND METHOD OF MANUFACTURING THE SAME
JP5246182B2 (en) 2010-02-24 2013-07-24 ライオン株式会社 Eye drops, preservatives and preservatives
CA2790682C (en) 2010-03-03 2020-11-24 Neocutis Sa Compositions and methods for the treatment of skin diseases and disorders using antimicrobial peptide sequestering compounds
US10238102B2 (en) 2010-04-12 2019-03-26 Exosect Limited Control of arthropods in animal environments
US8211450B2 (en) 2010-05-05 2012-07-03 Senju Usa, Inc. Ophthalmic composition
CN102260252A (en) * 2010-05-24 2011-11-30 盟科医药技术(上海)有限公司 Novel oxazolidinone used for treating bacterial infection
RU2472505C2 (en) 2010-12-07 2013-01-20 Общество с ограниченной ответственностью "Экохимтех" Therapeutic antimalaria drug based on antimalaria agent and probiotic
EP2654757A1 (en) * 2010-12-22 2013-10-30 Entarco SA The use of spinosyns and spinosyn compositions as local anesthetics and as antiarrhythmic agents
NZ611476A (en) 2010-12-27 2015-10-30 Intervet Int Bv Topical localized isoxazoline formulation
WO2012092320A2 (en) 2010-12-29 2012-07-05 Nichamin Louis D Eye treatment
US20130324538A1 (en) 2011-02-10 2013-12-05 Noëlle Gauvry Isoxazoline derivatives for controlling invertebrate pests
SI2683723T1 (en) 2011-03-10 2016-07-29 Zoetis Services Llc Spirocyclic isoxazoline derivatives as antiparasitic agents
KR102165246B1 (en) * 2011-04-05 2020-10-13 옵토솔브 리서치 앤드 디벨롭먼트 리미티드 Ophthalmic treatments
PT3172964T (en) * 2011-09-12 2020-11-30 Boehringer Ingelheim Animal Health Usa Inc Parasiticidal compositions comprising an isoxazoline active agent, method and uses thereof
CN102552114A (en) 2012-03-19 2012-07-11 段亚东 Metronidazole ophthalmic gel and preparation method and application thereof
US9345522B2 (en) 2012-05-22 2016-05-24 Matthew Songer Bone fixation screw and method
HRP20180861T1 (en) 2012-08-31 2018-07-13 Zoetis Services Llc Crystalline forms of 1-(5'-(5-(3,5-dichloro-4-fluorophenyl)-5-(trifluoromethyl)-4,5-dihydroisoxazol-3-yl)-3'h-spiro[azetidine-3,1'-isobenzofuran]-1-yl)-2-(methylsulfonyl)ethanone
US9095566B1 (en) 2013-06-28 2015-08-04 Edward Quicksilver Yavitz Eyelash and eyelid margin infections
US9233118B2 (en) 2013-07-08 2016-01-12 Galderma S.A. Treatment of papulopustular rosacea with ivermectin
CA2917815C (en) 2013-07-29 2022-08-30 Attillaps Holdings Organophosphates for treating afflictions of the skin
WO2019126541A1 (en) 2017-12-20 2019-06-27 Attillaps Holdings Treatment of ophthalmological conditions with acetylcholinesterase inhibitors
JP6581586B2 (en) * 2013-12-20 2019-09-25 インターベット インターナショナル ベー． フェー． Isoxazoline compositions and their use in the prevention or treatment of parasite infestation in animals
US10172902B2 (en) 2014-05-28 2019-01-08 Lunovus Llc Ocular eyelid scrub composition for the treatment of demodex blepharitis
PT3157534T (en) 2014-06-19 2022-08-04 Attillaps Holdings Acetylcholinesterase inhibitors for treatment of dermatological conditions
TW201625564A (en) 2014-07-23 2016-07-16 陶氏農業科學公司 Molecules with certain insecticidal effects and related intermediates, compositions and methods (2)
US20170232024A1 (en) 2014-08-04 2017-08-17 Jerry Tan Eye Surgery Pte Ltd Pharmaceutical compositions for demodex related blepharitis and eyelid crusting
US9463201B2 (en) 2014-10-19 2016-10-11 M.G. Therapeutics Ltd Compositions and methods for the treatment of meibomian gland dysfunction
CA2965524C (en) * 2014-11-03 2020-04-14 Zoetis Services Llc Palatable chewable veterinary composition
CA2971296A1 (en) * 2014-12-22 2016-06-30 Intervet International B.V. Use of isoxazoline compounds for treating demodicosis
RU2691412C2 (en) * 2015-02-24 2019-06-13 Дзе Боард Оф Трастис Оф Дзе Юниверсити Оф Иллинойс Methods and compositions for treating dry eye disease and other eye diseases
PY1609250A (en) 2015-02-26 2018-03-01 Merial Inc Long-acting injectable formulations comprising an active agent isoxazoline, methods and uses thereof
US20160287566A1 (en) 2015-04-04 2016-10-06 Thomas Lynn Busby Anti-demodectic active agents and topical compositions for the treatment of demodicosis in humans and animals
CN107750159B (en) * 2015-06-23 2021-10-29 英特维特国际股份有限公司 Isoxazoline solution containing vitamins for disinfection of drinking water
US20170024748A1 (en) 2015-07-22 2017-01-26 Patient Doctor Technologies, Inc. Guided discussion platform for multiple parties
JP2018531912A (en) * 2015-09-03 2018-11-01 アグリメティス，エルエルシー Spinosyn derivatives as insecticides
AU2016318336B2 (en) 2015-09-10 2018-09-27 Corteva Agriscience Llc Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
CA3000088A1 (en) 2015-09-28 2017-04-06 Azura Ophthalmics Ltd. Thiol and disulfide-containing agents for increasing meibomian gland lipid secretion
UY37137A (en) 2016-02-24 2017-09-29 Merial Inc ANTIPARASITARY COMPOUNDS OF ISOXAZOLINE, INJECTABLE FORMULATIONS OF PROLONGED ACTION THAT INCLUDE THEM, METHODS AND USES OF THE SAME
HUE056909T2 (en) 2016-04-06 2022-04-28 Boehringer Ingelheim Animal Health Usa Inc Process for the preparation of enantiomerically enriched isoxazoline compounds - crystalline toluene solvate of (s)-afoxolaner
KR20190022476A (en) 2016-04-12 2019-03-06 일루스트리스 파마슈티컬즈 인코포레이티드 Composition for topical application of compounds
KR102467347B1 (en) 2016-04-15 2022-11-14 바이엘 애니멀 헬스 게엠베하 Pyrazolopyrimidine derivatives
WO2018081733A1 (en) 2016-10-31 2018-05-03 The California Institute For Biomedical Research Methods and compositions for preventing vector-borne disease transmission
CN119157876A (en) 2017-12-15 2024-12-20 塔苏斯制药有限公司 Isoxazoline anthelmintic formulations and methods for treating blepharitis
CA3107590A1 (en) 2018-07-27 2020-01-30 Aperta Biosciences, Llc Spinosyn formulations for treatment of demodex-induced ocular and facial conditions
RS66315B1 (en) 2018-09-05 2025-01-31 Zoetis Services Llc Palatable antiparasitic formulations
WO2020202111A1 (en) 2019-04-04 2020-10-08 Tarsus Pharmaceuticals, Inc. Systemic isoxazoline parasiticides for vector-borne and viral disease treatment or prophylaxis
US20220249445A1 (en) 2019-06-19 2022-08-11 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
AU2020295570A1 (en) 2019-06-19 2022-02-10 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
CA3146043A1 (en) 2019-07-22 2021-01-28 Intervet International B.V. Soft chewable veterinary dosage form
CA3152740A1 (en) 2019-08-28 2021-03-04 Horizon Therapeutics Ireland Dac Methods for the treatment of thyroid eye disease
WO2021243014A1 (en) 2020-05-28 2021-12-02 Horizon Therapeutics Ireland Dac Methods for the treatment of idiopathic orbital inflammation and related conditions

Also Published As

Publication number Publication date
AU2023200843B2 (en) 2025-04-03
PL3723739T3 (en) 2024-09-16
IL275339B2 (en) 2024-03-01
AU2025204628A1 (en) 2025-07-10
CA3085787A1 (en) 2019-06-20
BR112020012018A2 (en) 2020-11-24
US20220354830A1 (en) 2022-11-10
EP4397375A2 (en) 2024-07-10
WO2019118928A1 (en) 2019-06-20
US12364685B2 (en) 2025-07-22
NZ766141A (en) 2024-01-26
US11752137B2 (en) 2023-09-12
IL275339A (en) 2020-07-30
US20230301971A1 (en) 2023-09-28
US20250312318A1 (en) 2025-10-09
EP4397375A3 (en) 2024-09-25
MX2020006309A (en) 2021-01-29
CN111655241B (en) 2024-10-15
US20250127762A1 (en) 2025-04-24
US20230293496A1 (en) 2023-09-21
KR20250059552A (en) 2025-05-02
KR20200111177A (en) 2020-09-28
US20220362218A1 (en) 2022-11-17
CN119157876A (en) 2024-12-20
CN119174758A (en) 2024-12-24
KR20250057155A (en) 2025-04-28
KR20250065422A (en) 2025-05-12
AU2018385766B2 (en) 2022-12-01
RU2020122841A (en) 2022-01-18
SI3723739T1 (en) 2024-08-30
AU2023200843A1 (en) 2023-03-16
US10835517B2 (en) 2020-11-17
US20210077466A1 (en) 2021-03-18
US20210077465A1 (en) 2021-03-18
US11690827B2 (en) 2023-07-04
US20210196689A1 (en) 2021-07-01
IL307992A (en) 2023-12-01
DK3723739T3 (en) 2024-06-17
AU2018385766A1 (en) 2020-07-23
US12213964B2 (en) 2025-02-04
IL307992B1 (en) 2024-11-01
US20220354829A1 (en) 2022-11-10
HUE067461T2 (en) 2024-10-28
IL316352A (en) 2024-12-01
EP3723739A4 (en) 2022-04-20
US11690826B2 (en) 2023-07-04
JP2021506971A (en) 2021-02-22
EP3723739B1 (en) 2024-03-27
CN111655241A (en) 2020-09-11
ZA202004155B (en) 2023-01-25
US20190183862A1 (en) 2019-06-20
IL275339B1 (en) 2023-11-01
US20230190711A1 (en) 2023-06-22
EP3723739A1 (en) 2020-10-21
ES2981130T3 (en) 2024-10-07
US20220054457A2 (en) 2022-02-24
US20250017908A1 (en) 2025-01-16
MX2024000828A (en) 2024-02-08
US12171750B2 (en) 2024-12-24
PT3723739T (en) 2024-06-21
US20250312317A1 (en) 2025-10-09
JP2024038449A (en) 2024-03-19
FI3723739T3 (en) 2024-06-19
US11197847B2 (en) 2021-12-14

Similar Documents

Publication Publication Date Title
IL307992B1 (en) Parasitic formulations containing isoxazoline and methods for treating blepharitis
JP7012075B2 (en) Pharmaceutical composition for use in the treatment of blepharitis
Sandford et al. Therapeutic potential of castor oil in managing blepharitis, meibomian gland dysfunction and dry eye
Del Rosso Adult seborrheic dermatitis: a status report on practical topical management
KR102097663B1 (en) Compositions and treatment for eye diseases and disorders
ES2750123T3 (en) Compositions and methods for non-surgical treatment of ptosis
CA3045733A1 (en) Compositions comprising tacrolimus for the treatment of intraocular inflammatory eye diseases
US10406203B2 (en) Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
JP2019532931A5 (en)
MX2021016055A (en) FORMULATIONS AND METHODS OF ISOXAZOLINE PARASITICIDES FOR THE TREATMENT OF BLEPHARITIS.
JP5153948B1 (en) Allergic rhinitis coating agent
US9011943B2 (en) Compositions and methods for alleviating skin disorders
Hakim et al. Medical management of blepharitis
Day et al. Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension
DE102010026696A1 (en) Use of a grease pencil for medical application of active ingredients on the edge of the eyelid, for e.g. treating allergic diseases of the eye, changes in intraocular pressure, preferably glaucoma, and inflammations of the eye
US20220133830A1 (en) Topical composition for control of demodex
RU2022100077A (en) ISOXAZOLINE PARASITICIDAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLEPHARITIS
NZ766141B2 (en) Isoxazoline parasiticide formulations and methods for treating blepharitis
US20200093887A1 (en) Ophthalmic treatment composition and vehicle for delivery of pharmaceutical substances or therapeutic agents
CH712627A2 (en) Hair growth promoting composition and application.
HK1210968B (en) Compositions and treatment for eye diseases and disorders